APTOAptose Biosciences Inc.

Nasdaq aptose.com


$ 0.41 $ 0.00 (-1.19 %)    

Friday, 23-Aug-2024 10:47:19 EDT
QQQ $ 476.56 $ 1.42 (0.3 %)
DIA $ 412.95 $ 0.17 (0.04 %)
SPY $ 561.57 $ 0.77 (0.14 %)
TLT $ 97.97 $ -0.17 (-0.17 %)
GLD $ 233.38 $ 0.63 (0.27 %)
$ 0.39
$ 0.41 x 300
-- x --
-- - --
$ 0.38 - $ 4.26
142,593
na
7.06M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-22-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 05-04-2021 03-31-2021 10-Q
15 03-23-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aptose-biosciences-q2-2024-gaap-eps-043-beats-086-estimate

Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(...

 hc-wainwright--co-reiterates-buy-on-aptose-biosciences-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $7 pri...

 aptose-showcases-clinical-and-preclinical-results-for-tuspetinib-tus-at-the-2024-eha-hybrid-congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or r...

 aptose-biosciences-shares-move-higher-traders-circulate-zacks-article-titled-aptose-biosciences-upgraded-to-buy-what-does-it-mean-for-the-stock

https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock

Core News & Articles

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology...

 canaccord-genuity-maintains-buy-on-aptose-biosciences-lowers-price-target-to-6

Canaccord Genuity analyst John Newman maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and lowers the price target from...

 aptose-biosciences-q1-eps-073-beats-074-estimate

Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(...

 piper-sandler-maintains-overweight-on-aptose-biosciences-maintains-5-price-target

Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price ta...

 hc-wainwright--co-maintains-buy-on-aptose-biosciences-maintains-23-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $23 pri...

 aptose-biosciences-q4-eps-144-beats-159-estimate

Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(...

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 piper-sandler-maintains-overweight-on-aptose-biosciences-lowers-price-target-to-5-report-released-on-31-january-2024

Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and lowers the price targ...

Core News & Articles

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (N...

 why-tellurian-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hi...

Core News & Articles

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company develop...

 rbc-capital-maintains-outperform-on-aptose-biosciences-lowers-price-target-to-18

RBC Capital analyst Gregory Renza maintains Aptose Biosciences (NASDAQ:APTO) with a Outperform and lowers the price target f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION